{
  "metformin_cancer": {
    "query": "Evaluate repurposing opportunities for Metformin (small molecule) in Oncology (cancer)",
    "tasks": [
      "Analyze unmet medical needs in Oncology therapy",
      "Assess competitive products and market dynamics for Oncology",
      "Search clinical trial registries for studies of Metformin in Oncology",
      "Review patent landscape focusing on Metformin Oncology",
      "Evaluate global market size and growth projections for Oncology",
      "Identify key companies and therapies in cancer area",
      "Examine manufacturing and API sourcing considerations for Metformin",
      "Monitor recent scientific publications on Metformin and Oncology",
      "Check regulatory status and approvals of Metformin in new indication",
      "Draft strategic recommendations for repurposing Metformin into Oncology"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global Oncology Drug Market Forecast (USD Billions)",
        "data": [
          {
            "year": "2022",
            "value": 160
          },
          {
            "year": "2023",
            "value": 165
          },
          {
            "year": "2024",
            "value": 173
          },
          {
            "year": "2025",
            "value": 182
          },
          {
            "year": "2026",
            "value": 190
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2024)",
        "data": [
          {
            "company": "Roche",
            "share": "20%"
          },
          {
            "company": "Novartis",
            "share": "18%"
          },
          {
            "company": "Pfizer",
            "share": "15%"
          },
          {
            "company": "Others",
            "share": "~47%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "India",
            "q2_2024": 120,
            "q3_2024": 150,
            "qoq_growth": "+25%"
          },
          {
            "country": "China",
            "q2_2024": 80,
            "q3_2024": 100,
            "qoq_growth": "+25%"
          },
          {
            "country": "Mexico",
            "q2_2024": 30,
            "q3_2024": 35,
            "qoq_growth": "+17%"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 50
          },
          {
            "year": 2023,
            "price": 55
          },
          {
            "year": 2024,
            "price": 53
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "Dependence on India/China; low API price volatility"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Metformin Clinical Trial Landscape",
        "description": "Multiple trials are evaluating Metformin's anticancer effects across various tumor types."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 2,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 8,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 2,
            "color": "amber"
          }
        ],
        "description": "Predominance of Phase II trials reflects exploratory studies in oncology contexts."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "Bristol-Myers Squibb",
            "trial_count": 3,
            "focus": "Breast, Colon Cancer"
          },
          {
            "sponsor": "NIH",
            "trial_count": 2,
            "focus": "Lung, Prostate Cancer"
          },
          {
            "sponsor": "Academic Consortia",
            "trial_count": 2,
            "focus": "Pancreatic Cancer"
          }
        ],
        "description": "Mix of industry and academic sponsors investigating Metformin's role in cancer."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "Original diabetes patents expired; weak patents on formulation/combos"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "All core patents expired by 2017; some process patents to 2025"
          },
          {
            "label": "FTO Status",
            "value": "Low risk due to expiry of key patents"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "Pancreatic and colon cancer (metabolic mechanism)",
        "medium_risk_areas": "Breast cancer, multiple myeloma (need dosing claims)",
        "low_priority": "Hematologic malignancies (less direct mechanism)"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 2
          },
          {
            "year": 2021,
            "count": 3
          },
          {
            "year": 2022,
            "count": 1
          },
          {
            "year": 2023,
            "count": 1
          },
          {
            "year": 2024,
            "count": 0
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "US7654321B2",
          "owner": "BMS",
          "key_claim": "Metformin to inhibit tumor growth"
        },
        {
          "patent": "EP1234567A1",
          "owner": "PharmaCo",
          "key_claim": "Metformin formulation for oncology"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "File method-of-use patents for specific cancer indications",
          "Develop novel combination therapies covered by patents"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "Interference with cancer metabolism; strong rationale"
          },
          {
            "label": "Clinical Evidence",
            "value": "Retrospective studies suggest reduced tumor growth with metformin"
          },
          {
            "label": "Competition",
            "value": "Many generic options; niche for adjunct therapy"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "High (Diabetes)",
            "current_level": "green",
            "new": "Medium (Oncology)",
            "new_level": "yellow"
          },
          {
            "dimension": "Clinical Evidence",
            "current": "Strong",
            "current_level": "green",
            "new": "Modest",
            "new_level": "yellow"
          },
          {
            "dimension": "Mechanistic Rationale",
            "current": "Moderate",
            "current_level": "green",
            "new": "Strong",
            "new_level": "green"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "Metformin Shows Promise in New Cancer Study",
          "source": "Reuters",
          "date": "2026-01-10",
          "summary": "A recent study indicates Metformin may improve survival in colon cancer patients."
        },
        {
          "headline": "Clinical Trial Launched for Metformin in Ovarian Cancer",
          "source": "PharmaTimes",
          "date": "2025-11-05",
          "summary": "Biotech firm announces Phase II trial to test Metformin for ovarian cancer treatment."
        }
      ],
      "publications": [
        {
          "title": "Metformin inhibits tumor growth via AMPK in colon cancer",
          "journal": "Cell Metabolism",
          "year": 2025,
          "summary": "Laboratory study shows Metformin significantly slowed colon tumor growth in mice."
        },
        {
          "title": "Effect of Metformin on Chemotherapy Efficacy",
          "journal": "Journal of Oncology",
          "year": 2026,
          "summary": "Clinical trial data shows added benefit of Metformin with standard chemo in advanced breast cancer."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Metformin.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/metformin_cancer_repurposing_report.pdf"
    }
  },
  "sildenafil_altitude": {
    "query": "Evaluate repurposing opportunities for Sildenafil (small molecule) in High Altitude Pulmonary Edema (pulmonary)",
    "tasks": [
      "Analyze unmet medical needs in High Altitude Pulmonary Edema therapy",
      "Assess competitive products and market dynamics for pulmonary conditions",
      "Search clinical trial registries for studies of Sildenafil in High Altitude Pulmonary Edema",
      "Review patent landscape focusing on Sildenafil High Altitude Pulmonary Edema",
      "Evaluate global market size and growth projections for pulmonary conditions",
      "Identify key companies and therapies in pulmonary area",
      "Examine manufacturing and API sourcing considerations for Sildenafil",
      "Monitor recent scientific publications on Sildenafil and high-altitude medicine",
      "Check regulatory status and approvals of Sildenafil in new indication",
      "Draft strategic recommendations for repurposing Sildenafil into High Altitude Pulmonary Edema"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global Pulmonary Hypertension & Altitude Sickness Market Forecast (USD Millions)",
        "data": [
          {
            "year": "2022",
            "value": 450
          },
          {
            "year": "2023",
            "value": 470
          },
          {
            "year": "2024",
            "value": 490
          },
          {
            "year": "2025",
            "value": 510
          },
          {
            "year": "2026",
            "value": 540
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2024)",
        "data": [
          {
            "company": "Pfizer (Revatio)",
            "share": "65%"
          },
          {
            "company": "Novartis (Adempas)",
            "share": "10%"
          },
          {
            "company": "Generic Suppliers",
            "share": "~25%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "China",
            "q2_2024": 90,
            "q3_2024": 110,
            "qoq_growth": "+22%"
          },
          {
            "country": "India",
            "q2_2024": 60,
            "q3_2024": 75,
            "qoq_growth": "+25%"
          },
          {
            "country": "Germany",
            "q2_2024": 20,
            "q3_2024": 25,
            "qoq_growth": "+25%"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 300
          },
          {
            "year": 2023,
            "price": 290
          },
          {
            "year": 2024,
            "price": 295
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "China/India APIs; counterfeit risks in informal markets"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Sildenafil Clinical Trial Landscape",
        "description": "Sildenafil trials are focused on pulmonary conditions including altitude sickness and HAPE."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 1,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 4,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 1,
            "color": "amber"
          }
        ],
        "description": "Several Phase II studies explore efficacy for acute mountain sickness."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "University Research Centers",
            "trial_count": 3,
            "focus": "HAPE prevention"
          },
          {
            "sponsor": "Defense Research Labs",
            "trial_count": 1,
            "focus": "Altitude Adaptation"
          },
          {
            "sponsor": "Pharmaceutical Company",
            "trial_count": 2,
            "focus": "Pulmonary Hypertension"
          }
        ],
        "description": "Research led by military and academia on altitude applications."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "Composition patent expired (2012); some delivery/formulation patents exist"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "Core patents expired ~2012; formulation patents to 2023"
          },
          {
            "label": "FTO Status",
            "value": "Generally open; caution on use in pulmonary hypertension claims"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "Altitude sickness prophylaxis (mechanistic alignment)",
        "medium_risk_areas": "Pulmonary hypertension (existing patents)",
        "low_priority": "Cardiac uses beyond current labels"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 1
          },
          {
            "year": 2021,
            "count": 1
          },
          {
            "year": 2022,
            "count": 0
          },
          {
            "year": 2023,
            "count": 1
          },
          {
            "year": 2024,
            "count": 0
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "US10987654B2",
          "owner": "Pfizer",
          "key_claim": "PDE5 inhibitors for altitude sickness"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "Target formulation patents for mountain-use dosage",
          "Claim methods specific to altitude acclimatization"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "Vasodilation improves oxygenation at altitude"
          },
          {
            "label": "Clinical Evidence",
            "value": "Some pilot studies in mountaineers exist"
          },
          {
            "label": "Strategic Fit",
            "value": "Distinct niche market; complements cardiovascular portfolio"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "High (ED)",
            "current_level": "green",
            "new": "Low (Altitude)",
            "new_level": "yellow"
          },
          {
            "dimension": "Regulatory Hurdles",
            "current": "Low",
            "current_level": "green",
            "new": "Moderate",
            "new_level": "yellow"
          },
          {
            "dimension": "Competition",
            "current": "Medium",
            "current_level": "yellow",
            "new": "Low",
            "new_level": "green"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "Pfizer Trials Sildenafil for Mountain Climbing",
          "source": "BBC News",
          "date": "2025-12-01",
          "summary": "Pfizer announces research into use of Viagra to combat altitude sickness."
        },
        {
          "headline": "Sildenafil approved for rare pulmonary condition",
          "source": "The Lancet News",
          "date": "2026-02-15",
          "summary": "Regulator approves novel indication to relieve high altitude pulmonary edema."
        }
      ],
      "publications": [
        {
          "title": "Sildenafil improves oxygenation at high altitude",
          "journal": "NEJM",
          "year": 2025,
          "summary": "Randomized trial found reduced symptoms in climbers using Sildenafil vs placebo."
        },
        {
          "title": "PDE5 inhibitors and Altitude Hypoxia",
          "journal": "Respiratory Medicine",
          "year": 2024,
          "summary": "Review of evidence for PDE5 inhibitor benefits in hypoxic conditions."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Sildenafil.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/sildenafil_altitude_repurposing_report.pdf"
    }
  },
  "adalimumab_lungfibrosis": {
    "query": "Evaluate repurposing opportunities for Adalimumab (biologic) in Idiopathic Pulmonary Fibrosis (pulmonology)",
    "tasks": [
      "Analyze unmet medical needs in Idiopathic Pulmonary Fibrosis therapy",
      "Assess competitive products and market dynamics for pulmonology conditions",
      "Search clinical trial registries for studies of Adalimumab in Idiopathic Pulmonary Fibrosis",
      "Review patent landscape focusing on Adalimumab Idiopathic Pulmonary Fibrosis",
      "Evaluate global market size and growth projections for pulmonology conditions",
      "Identify key companies and therapies in autoimmune lung disease area",
      "Examine manufacturing and API sourcing considerations for Adalimumab",
      "Monitor recent scientific publications on Adalimumab and lung fibrosis",
      "Check regulatory status and approvals of Adalimumab in new indication",
      "Draft strategic recommendations for repurposing Adalimumab into Idiopathic Pulmonary Fibrosis"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global Lung Disease Biologics Market Forecast (USD Billions)",
        "data": [
          {
            "year": "2022",
            "value": 2.1
          },
          {
            "year": "2023",
            "value": 2.3
          },
          {
            "year": "2024",
            "value": 2.6
          },
          {
            "year": "2025",
            "value": 3.0
          },
          {
            "year": "2026",
            "value": 3.4
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2026)",
        "data": [
          {
            "company": "Boehringer Ingelheim",
            "share": "30%"
          },
          {
            "company": "Roche (Actemra)",
            "share": "25%"
          },
          {
            "company": "Galapagos",
            "share": "15%"
          },
          {
            "company": "Others",
            "share": "~30%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "EU (Germany)",
            "q2_2024": 5,
            "q3_2024": 7,
            "qoq_growth": "+40%"
          },
          {
            "country": "USA",
            "q2_2024": 3,
            "q3_2024": 4,
            "qoq_growth": "+33%"
          },
          {
            "country": "India",
            "q2_2024": 2,
            "q3_2024": 2,
            "qoq_growth": "0%"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 8000
          },
          {
            "year": 2023,
            "price": 8200
          },
          {
            "year": 2024,
            "price": 8100
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "Complex manufacturing; potential biosimilar competition"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Adalimumab Clinical Trial Landscape",
        "description": "Investigation into anti-TNF therapies for lung fibrosis is nascent, with few active studies."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 0,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 3,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 1,
            "color": "amber"
          }
        ],
        "description": "Predominantly Phase II trials targeting fibrotic lung disease."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "AbbVie",
            "trial_count": 1,
            "focus": "IPF"
          },
          {
            "sponsor": "Academic Consortium",
            "trial_count": 2,
            "focus": "Autoimmune Lung Disease"
          }
        ],
        "description": "Single industry study with additional investigator-led trials."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "Biologic composition patents active until 2026; method patents exist for autoimmune uses"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "Core patents expire ~2026; some EU extension til 2029"
          },
          {
            "label": "FTO Status",
            "value": "High risk due to strong method-of-use patents by multiple companies"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "Fibrotic lung diseases (novel indication claims)",
        "medium_risk_areas": "Other autoimmune ILDs (patent overlap)",
        "low_priority": "Broad inflammatory uses"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 3
          },
          {
            "year": 2021,
            "count": 4
          },
          {
            "year": 2022,
            "count": 2
          },
          {
            "year": 2023,
            "count": 3
          },
          {
            "year": 2024,
            "count": 1
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "US9876543B2",
          "owner": "AbbVie",
          "key_claim": "TNF inhibitors for lung fibrosis"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "Focus on orphan indications to extend exclusivity",
          "Combine with biomarkers to differentiate usage"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "Anti-inflammatory may slow fibrosis progression"
          },
          {
            "label": "Clinical Signal",
            "value": "Mixed results in IPF; theoretical benefit"
          },
          {
            "label": "Manufacturing Challenge",
            "value": "Biologic production is complex and costly"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "High (RA/IBD)",
            "current_level": "green",
            "new": "Low (IPF)",
            "new_level": "yellow"
          },
          {
            "dimension": "Scientific Rationale",
            "current": "Established",
            "current_level": "green",
            "new": "Preliminary",
            "new_level": "yellow"
          },
          {
            "dimension": "Competition",
            "current": "Low",
            "current_level": "green",
            "new": "Medium",
            "new_level": "yellow"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "New Study on TNF Inhibitors in Lung Fibrosis",
          "source": "Nature News",
          "date": "2025-10-20",
          "summary": "Researchers are exploring anti-TNF therapies for pulmonary fibrosis in early clinical studies."
        }
      ],
      "publications": [
        {
          "title": "TNF blockade in pulmonary fibrosis: experimental insights",
          "journal": "American Journal of Respiratory and Critical Care Medicine",
          "year": 2025,
          "summary": "Review article summarizing preclinical data on TNF inhibition in fibrotic lung models."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Adalimumab.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/adalimumab_lungfibrosis_repurposing_report.pdf"
    }
  },
  "fluoxetine_neurodegenerative": {
    "query": "Evaluate repurposing opportunities for Fluoxetine (small molecule) in Alzheimer's Disease (neurology)",
    "tasks": [
      "Analyze unmet medical needs in Alzheimer's Disease therapy",
      "Assess competitive products and market dynamics for neurology conditions",
      "Search clinical trial registries for studies of Fluoxetine in Alzheimer's Disease",
      "Review patent landscape focusing on Fluoxetine Alzheimer's Disease",
      "Evaluate global market size and growth projections for neurology conditions",
      "Identify key companies and therapies in CNS disorders area",
      "Examine manufacturing and API sourcing considerations for Fluoxetine",
      "Monitor recent scientific publications on Fluoxetine and neurodegeneration",
      "Check regulatory status and approvals of Fluoxetine in new indication",
      "Draft strategic recommendations for repurposing Fluoxetine into Alzheimer's Disease"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global Alzheimer's Disease Drug Market Forecast (USD Billions)",
        "data": [
          {
            "year": "2022",
            "value": 3.2
          },
          {
            "year": "2023",
            "value": 3.4
          },
          {
            "year": "2024",
            "value": 3.7
          },
          {
            "year": "2025",
            "value": 4.0
          },
          {
            "year": "2026",
            "value": 4.4
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2024)",
        "data": [
          {
            "company": "Biogen (Aduhelm)",
            "share": "40%"
          },
          {
            "company": "Eli Lilly",
            "share": "20%"
          },
          {
            "company": "Roche",
            "share": "15%"
          },
          {
            "company": "Others",
            "share": "~25%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "China",
            "q2_2024": 50,
            "q3_2024": 60,
            "qoq_growth": "+20%"
          },
          {
            "country": "India",
            "q2_2024": 40,
            "q3_2024": 50,
            "qoq_growth": "+25%"
          },
          {
            "country": "Brazil",
            "q2_2024": 10,
            "q3_2024": 12,
            "qoq_growth": "+20%"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 40
          },
          {
            "year": 2023,
            "price": 42
          },
          {
            "year": 2024,
            "price": 43
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "Multiple generic sources; largely stable pricing"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Fluoxetine Clinical Trial Landscape",
        "description": "Fluoxetine trials in neurodegenerative disease are limited, focusing on symptomatic outcomes."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 1,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 2,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 1,
            "color": "amber"
          }
        ],
        "description": "Early-phase trials predominate; no large Phase III studies yet."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "University Hospitals",
            "trial_count": 1,
            "focus": "Alzheimer's cognitive effects"
          },
          {
            "sponsor": "National Institutes of Health",
            "trial_count": 1,
            "focus": "Parkinson's depression"
          },
          {
            "sponsor": "Biotech Startup",
            "trial_count": 1,
            "focus": "Dementia-related agitation"
          }
        ],
        "description": "Mixed sponsorship suggests experimental exploration in neurology."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "Original antidepressant patents expired; formulation patents also expired"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "All related patents expired by early 2000s"
          },
          {
            "label": "FTO Status",
            "value": "Open FTO; no known constraints for repurposing"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "Alzheimer's agitation (well-known serotonergic pathway)",
        "medium_risk_areas": "Neuroprotection (less direct evidence)",
        "low_priority": "Parkinson's motor symptoms"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 0
          },
          {
            "year": 2021,
            "count": 0
          },
          {
            "year": 2022,
            "count": 0
          },
          {
            "year": 2023,
            "count": 0
          },
          {
            "year": 2024,
            "count": 0
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "US11223344B2",
          "owner": "Academic",
          "key_claim": "SSRIs for cognitive decline"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "Leverage expired patent for generic branding plus new formulations",
          "Explore combination patents with cognitive enhancers"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "Neuroprotective effects via serotonin; unproven"
          },
          {
            "label": "Clinical Signal",
            "value": "Case reports, but no clear benefit in trials"
          },
          {
            "label": "Safety Profile",
            "value": "Well-understood SSRIs; low safety concern for elderly"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "High (Depression)",
            "current_level": "green",
            "new": "Low (Alzheimer's)",
            "new_level": "yellow"
          },
          {
            "dimension": "Risk of Off-Label Use",
            "current": "Low",
            "current_level": "green",
            "new": "Moderate",
            "new_level": "yellow"
          },
          {
            "dimension": "Competition",
            "current": "Low",
            "current_level": "green",
            "new": "High (CNS drugs)",
            "new_level": "red"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "Fluoxetine Shows New Neurological Benefits in Early Study",
          "source": "MedPage Today",
          "date": "2025-08-10",
          "summary": "Preliminary research suggests Fluoxetine may improve cognitive function in early Alzheimer's patients."
        }
      ],
      "publications": [
        {
          "title": "SSRIs and neuroinflammation: implications for Alzheimer's disease",
          "journal": "Journal of Neurochemistry",
          "year": 2025,
          "summary": "Review article discussing the potential neuroprotective effects of SSRIs in neurodegenerative conditions."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Fluoxetine.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/fluoxetine_neurodegenerative_repurposing_report.pdf"
    }
  },
  "pembrolizumab_NASH": {
    "query": "Evaluate repurposing opportunities for Pembrolizumab (biologic) in Non-Alcoholic Steatohepatitis (hepatology)",
    "tasks": [
      "Analyze unmet medical needs in Non-Alcoholic Steatohepatitis therapy",
      "Assess competitive products and market dynamics for hepatology conditions",
      "Search clinical trial registries for studies of Pembrolizumab in Non-Alcoholic Steatohepatitis",
      "Review patent landscape focusing on Pembrolizumab Non-Alcoholic Steatohepatitis",
      "Evaluate global market size and growth projections for hepatology conditions",
      "Identify key companies and therapies in immuno-oncology area",
      "Examine manufacturing and API sourcing considerations for Pembrolizumab",
      "Monitor recent scientific publications on Pembrolizumab and NASH",
      "Check regulatory status and approvals of Pembrolizumab in new indication",
      "Draft strategic recommendations for repurposing Pembrolizumab into Non-Alcoholic Steatohepatitis"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global NASH Treatment Market Forecast (USD Billions)",
        "data": [
          {
            "year": "2022",
            "value": 0.8
          },
          {
            "year": "2023",
            "value": 1.0
          },
          {
            "year": "2024",
            "value": 1.3
          },
          {
            "year": "2025",
            "value": 1.7
          },
          {
            "year": "2026",
            "value": 2.2
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2024)",
        "data": [
          {
            "company": "Intercept Pharmaceuticals",
            "share": "50%"
          },
          {
            "company": "Novartis",
            "share": "20%"
          },
          {
            "company": "Merck (Keytruda)",
            "share": "15%"
          },
          {
            "company": "Others",
            "share": "~15%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "USA",
            "q2_2024": 2,
            "q3_2024": 3,
            "qoq_growth": "+50%"
          },
          {
            "country": "EU (Belgium)",
            "q2_2024": 2,
            "q3_2024": 2,
            "qoq_growth": "0%"
          },
          {
            "country": "India",
            "q2_2024": 0,
            "q3_2024": 1,
            "qoq_growth": "+∞"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 6000
          },
          {
            "year": 2023,
            "price": 6200
          },
          {
            "year": 2024,
            "price": 6100
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "Single-source (Merck); high cost; supply chain concentrated"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Pembrolizumab Clinical Trial Landscape",
        "description": "Exploratory trials are evaluating immunotherapy effects in NASH."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 1,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 2,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 0,
            "color": "amber"
          }
        ],
        "description": "Only early-phase trials are underway for NASH."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "Merck",
            "trial_count": 1,
            "focus": "NASH Immunoediting"
          },
          {
            "sponsor": "Yale University",
            "trial_count": 1,
            "focus": "Liver Inflammation"
          },
          {
            "sponsor": "Academic Research",
            "trial_count": 1,
            "focus": "Metabolic Syndrome"
          }
        ],
        "description": "Collaboration between Merck and academic centers investigating NASH."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "Active patents on composition and use in cancers; no direct NASH claims"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "Key patents expire ~2028; potential new filings possible"
          },
          {
            "label": "FTO Status",
            "value": "High risk due to broad immuno-oncology patents, but NASH-specific claims absent"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "NASH fibrosis treatment (novel immuno-oncology indication)",
        "medium_risk_areas": "Other metabolic diseases (patent by analogy)",
        "low_priority": "Non-inflammatory indications"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 5
          },
          {
            "year": 2021,
            "count": 6
          },
          {
            "year": 2022,
            "count": 4
          },
          {
            "year": 2023,
            "count": 3
          },
          {
            "year": 2024,
            "count": 2
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "US12349876B2",
          "owner": "Merck",
          "key_claim": "PD-1 inhibitors for fibrotic disease"
        },
        {
          "patent": "WO2022123456A1",
          "owner": "Merck",
          "key_claim": "Immunotherapy in metabolic syndrome"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "Method-of-use claims for NASH treatment",
          "Patenting combination with anti-fibrotics"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "Immune modulation in liver pathology; novel approach"
          },
          {
            "label": "Clinical Signal",
            "value": "Early trials, some biomarkers suggest potential"
          },
          {
            "label": "Safety Considerations",
            "value": "Immune therapy risks in fatty liver disease"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "High (Oncology)",
            "current_level": "green",
            "new": "Low (NASH)",
            "new_level": "yellow"
          },
          {
            "dimension": "Safety Profile",
            "current": "Moderate",
            "current_level": "green",
            "new": "Moderate/High",
            "new_level": "amber"
          },
          {
            "dimension": "Competition",
            "current": "Very High",
            "current_level": "red",
            "new": "Moderate",
            "new_level": "yellow"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "Pembrolizumab Shows Anti-Fibrotic Activity in Mouse Model of NASH",
          "source": "ScienceDaily",
          "date": "2026-03-01",
          "summary": "Researchers report PD-1 blockade reduced liver fibrosis markers in a preclinical study."
        }
      ],
      "publications": [
        {
          "title": "Immune checkpoint therapy for liver diseases: new insights",
          "journal": "Hepatology",
          "year": 2025,
          "summary": "Review article discussing emerging roles of checkpoint inhibitors in liver disease."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Pembrolizumab.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/pembrolizumab_NASH_repurposing_report.pdf"
    }
  },
  "omeprazole_osteoporosis": {
    "query": "Evaluate repurposing opportunities for Omeprazole (small molecule) in Osteoporosis (endocrinology)",
    "tasks": [
      "Analyze unmet medical needs in Osteoporosis therapy",
      "Assess competitive products and market dynamics for endocrinology conditions",
      "Search clinical trial registries for studies of Omeprazole in Osteoporosis",
      "Review patent landscape focusing on Omeprazole Osteoporosis",
      "Evaluate global market size and growth projections for endocrinology conditions",
      "Identify key companies and therapies in gastroenterology to bone area",
      "Examine manufacturing and API sourcing considerations for Omeprazole",
      "Monitor recent scientific publications on Omeprazole and bone health",
      "Check regulatory status and approvals of Omeprazole in new indication",
      "Draft strategic recommendations for repurposing Omeprazole into Osteoporosis"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global Osteoporosis Drug Market Forecast (USD Billions)",
        "data": [
          {
            "year": "2022",
            "value": 10.5
          },
          {
            "year": "2023",
            "value": 11.0
          },
          {
            "year": "2024",
            "value": 11.4
          },
          {
            "year": "2025",
            "value": 11.8
          },
          {
            "year": "2026",
            "value": 12.3
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2024)",
        "data": [
          {
            "company": "AstraZeneca (Protonix)",
            "share": "35%"
          },
          {
            "company": "Pfizer (Prevacid)",
            "share": "25%"
          },
          {
            "company": "Kowa (Evista)",
            "share": "20%"
          },
          {
            "company": "Others",
            "share": "~20%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "India",
            "q2_2024": 100,
            "q3_2024": 120,
            "qoq_growth": "+20%"
          },
          {
            "country": "China",
            "q2_2024": 80,
            "q3_2024": 85,
            "qoq_growth": "+6%"
          },
          {
            "country": "Turkey",
            "q2_2024": 20,
            "q3_2024": 25,
            "qoq_growth": "+25%"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 100
          },
          {
            "year": 2023,
            "price": 105
          },
          {
            "year": 2024,
            "price": 102
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "Generics widespread; minimal supply risk"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Omeprazole Clinical Trial Landscape",
        "description": "Few trials examine PPI effects on bone health; evidence is largely from observational studies."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 0,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 1,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 1,
            "color": "amber"
          }
        ],
        "description": "Limited interventional studies; mostly association analyses."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "GSK",
            "trial_count": 1,
            "focus": "Bone Density Impact"
          },
          {
            "sponsor": "NIH",
            "trial_count": 1,
            "focus": "Gastro vs Bone Outcome"
          }
        ],
        "description": "Small-scale trials funded by pharma and government."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "PPIs composition patents expired; no bone-related claims exist"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "All omeprazole patents expired by 2010s"
          },
          {
            "label": "FTO Status",
            "value": "Open FTO; generic product widely available"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "Fracture prevention (focus on specific populations)",
        "medium_risk_areas": "Metabolic bone disease (broad prior art)",
        "low_priority": "General osteoporosis"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 0
          },
          {
            "year": 2021,
            "count": 1
          },
          {
            "year": 2022,
            "count": 0
          },
          {
            "year": 2023,
            "count": 1
          },
          {
            "year": 2024,
            "count": 0
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "US55667788B2",
          "owner": "GSK",
          "key_claim": "Delayed-release PPI formulations for bone health"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "Develop novel dosing strategies with IP coverage",
          "File patents on targeted delivery to bone tissue"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "PPIs may affect calcium uptake; indirect bone effects"
          },
          {
            "label": "Clinical Evidence",
            "value": "Data suggests long-term PPI use might reduce bone density"
          },
          {
            "label": "Market Potential",
            "value": "Limited by generics and established osteoporosis treatments"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "High (GERD)",
            "current_level": "green",
            "new": "Very Low",
            "new_level": "yellow"
          },
          {
            "dimension": "Evidence Strength",
            "current": "Moderate",
            "current_level": "green",
            "new": "Weak",
            "new_level": "yellow"
          },
          {
            "dimension": "Competition",
            "current": "Low",
            "current_level": "green",
            "new": "Very High",
            "new_level": "red"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "New Study Links Long-Term PPI Use to Bone Density Changes",
          "source": "Endocrine Today",
          "date": "2026-01-15",
          "summary": "Observational data show chronic Omeprazole users may have higher fracture risk."
        }
      ],
      "publications": [
        {
          "title": "Proton pump inhibitors and fracture risk: a clinical review",
          "journal": "Journal of Bone and Mineral Research",
          "year": 2025,
          "summary": "Review summarizing evidence of bone metabolism changes with chronic PPI therapy."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Omeprazole.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/omeprazole_osteoporosis_repurposing_report.pdf"
    }
  },
  "rituximab_parkinson": {
    "query": "Evaluate repurposing opportunities for Rituximab (biologic) in Parkinson's Disease (neurology)",
    "tasks": [
      "Analyze unmet medical needs in Parkinson's Disease therapy",
      "Assess competitive products and market dynamics for neurology conditions",
      "Search clinical trial registries for studies of Rituximab in Parkinson's Disease",
      "Review patent landscape focusing on Rituximab Parkinson's Disease",
      "Evaluate global market size and growth projections for neurology conditions",
      "Identify key companies and therapies in autoimmune neurology area",
      "Examine manufacturing and API sourcing considerations for Rituximab",
      "Monitor recent scientific publications on Rituximab and Parkinson's",
      "Check regulatory status and approvals of Rituximab in new indication",
      "Draft strategic recommendations for repurposing Rituximab into Parkinson's Disease"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global Parkinson's Disease Treatment Market Forecast (USD Billions)",
        "data": [
          {
            "year": "2022",
            "value": 6.0
          },
          {
            "year": "2023",
            "value": 6.2
          },
          {
            "year": "2024",
            "value": 6.5
          },
          {
            "year": "2025",
            "value": 6.8
          },
          {
            "year": "2026",
            "value": 7.0
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2024)",
        "data": [
          {
            "company": "AbbVie (Duodopa)",
            "share": "30%"
          },
          {
            "company": "Teva (Azilect)",
            "share": "20%"
          },
          {
            "company": "Roche",
            "share": "15%"
          },
          {
            "company": "Others",
            "share": "~35%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "EU (Germany)",
            "q2_2024": 5,
            "q3_2024": 6,
            "qoq_growth": "+20%"
          },
          {
            "country": "USA",
            "q2_2024": 4,
            "q3_2024": 5,
            "qoq_growth": "+25%"
          },
          {
            "country": "India",
            "q2_2024": 1,
            "q3_2024": 1,
            "qoq_growth": "0%"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 5000
          },
          {
            "year": 2023,
            "price": 4800
          },
          {
            "year": 2024,
            "price": 4900
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "Patent expired; biosimilar entry; moderate supply diversity"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Rituximab Clinical Trial Landscape",
        "description": "Investigations of B-cell depletion in Parkinson's disease are highly experimental."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 0,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 1,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 0,
            "color": "amber"
          }
        ],
        "description": "Only a handful of exploratory studies; no late-stage trials."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "Academic Research",
            "trial_count": 1,
            "focus": "Neuroinflammation in PD"
          }
        ],
        "description": "Preliminary study by an academic neurology group."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "Primary patents expired; method use patents for neurology sparse"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "Patents expired ~2016; biosimilar entries around 2020"
          },
          {
            "label": "FTO Status",
            "value": "Moderate risk; repurposing claims can be drafted new"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "Autoimmune neurology (MS, Parkinson's with autoimmune component)",
        "medium_risk_areas": "Idiopathic Parkinson's (less clear mechanism)",
        "low_priority": "Other movement disorders"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 1
          },
          {
            "year": 2021,
            "count": 1
          },
          {
            "year": 2022,
            "count": 1
          },
          {
            "year": 2023,
            "count": 0
          },
          {
            "year": 2024,
            "count": 0
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "EP99887766B1",
          "owner": "Roche",
          "key_claim": "Anti-CD20 antibodies in neurological disorders"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "New claims on B-cell roles in Parkinson's",
          "Combine with biomarkers for AD claims"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "Emerging idea of immune component; largely speculative"
          },
          {
            "label": "Clinical Signal",
            "value": "Very preliminary; few case studies"
          },
          {
            "label": "Patient Impact",
            "value": "High if effective; but risk of heavy immunosuppression"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "High (RA/Neuroimmunology)",
            "current_level": "green",
            "new": "Low",
            "new_level": "red"
          },
          {
            "dimension": "Scientific Plausibility",
            "current": "Established",
            "current_level": "green",
            "new": "Theoretical",
            "new_level": "yellow"
          },
          {
            "dimension": "Risk Factor",
            "current": "Moderate",
            "current_level": "green",
            "new": "High",
            "new_level": "red"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "Pilot Study of Rituximab in Parkinson's Shows Early Tolerability",
          "source": "Neurology Today",
          "date": "2025-09-12",
          "summary": "Initial small study suggests Rituximab is tolerated but no clear benefit yet in PD."
        }
      ],
      "publications": [
        {
          "title": "B cells in Parkinson's Disease pathology",
          "journal": "Movement Disorders",
          "year": 2025,
          "summary": "Research article exploring the potential role of B-cell depletion in Parkinson's models."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Rituximab.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/rituximab_parkinson_repurposing_report.pdf"
    }
  },
  "ketamine_chronic_pain": {
    "query": "Evaluate repurposing opportunities for Ketamine (small molecule) in Chronic Neuropathic Pain (pain)",
    "tasks": [
      "Analyze unmet medical needs in Chronic Neuropathic Pain therapy",
      "Assess competitive products and market dynamics for pain management",
      "Search clinical trial registries for studies of Ketamine in Chronic Neuropathic Pain",
      "Review patent landscape focusing on Ketamine Chronic Neuropathic Pain",
      "Evaluate global market size and growth projections for pain therapeutics",
      "Identify key companies and therapies in anesthesia and pain management area",
      "Examine manufacturing and API sourcing considerations for Ketamine",
      "Monitor recent scientific publications on Ketamine and chronic pain",
      "Check regulatory status and approvals of Ketamine in new indication",
      "Draft strategic recommendations for repurposing Ketamine into Chronic Neuropathic Pain"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global Chronic Pain Therapies Market Forecast (USD Billions)",
        "data": [
          {
            "year": "2022",
            "value": 15.0
          },
          {
            "year": "2023",
            "value": 15.5
          },
          {
            "year": "2024",
            "value": 16.0
          },
          {
            "year": "2025",
            "value": 16.8
          },
          {
            "year": "2026",
            "value": 17.5
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2024)",
        "data": [
          {
            "company": "Johnson & Johnson",
            "share": "25%"
          },
          {
            "company": "Mundipharma",
            "share": "20%"
          },
          {
            "company": "Depomed",
            "share": "15%"
          },
          {
            "company": "Others",
            "share": "~40%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "USA",
            "q2_2024": 50,
            "q3_2024": 55,
            "qoq_growth": "+10%"
          },
          {
            "country": "Mexico",
            "q2_2024": 10,
            "q3_2024": 12,
            "qoq_growth": "+20%"
          },
          {
            "country": "India",
            "q2_2024": 20,
            "q3_2024": 25,
            "qoq_growth": "+25%"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 20
          },
          {
            "year": 2023,
            "price": 22
          },
          {
            "year": 2024,
            "price": 23
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "Controlled substance; regulatory scrutiny"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Ketamine Clinical Trial Landscape",
        "description": "Multiple trials explore ketamine for chronic pain, reflecting growing interest in NMDA-targeted therapies."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 2,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 4,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 1,
            "color": "amber"
          }
        ],
        "description": "Several Phase II trials, few progressed to Phase III for chronic pain."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "Janssen",
            "trial_count": 2,
            "focus": "Treatment-Resistant Pain"
          },
          {
            "sponsor": "National Institutes of Health",
            "trial_count": 2,
            "focus": "Complex Regional Pain Syndrome"
          },
          {
            "sponsor": "University Pain Clinic",
            "trial_count": 1,
            "focus": "Neuropathic Pain Study"
          }
        ],
        "description": "Combination of industry and NIH-sponsored trials on ketamine pain use."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "Generic anesthetic; no current patents active on ketamine itself"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "All patents expired decades ago"
          },
          {
            "label": "FTO Status",
            "value": "Open FTO; only formulation patents possible"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "Neuropathic pain and depression (well-studied areas)",
        "medium_risk_areas": "Other chronic pain syndromes",
        "low_priority": "Acute pain"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 0
          },
          {
            "year": 2021,
            "count": 2
          },
          {
            "year": 2022,
            "count": 1
          },
          {
            "year": 2023,
            "count": 1
          },
          {
            "year": 2024,
            "count": 1
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "US66778899B2",
          "owner": "NewCo",
          "key_claim": "Ketamine metabolites for pain relief"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "Formulation patents (e.g. nasal sprays, patches)",
          "Combination therapy patents"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "NMDA antagonism directly addresses pain signaling"
          },
          {
            "label": "Clinical Evidence",
            "value": "Multiple studies show pain relief; off-label use is growing"
          },
          {
            "label": "Regulatory Status",
            "value": "Emerging approvals for depression; pain indications evolving"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "Medium (anesthesia)",
            "current_level": "yellow",
            "new": "High",
            "new_level": "green"
          },
          {
            "dimension": "Clinical Adoption",
            "current": "Low",
            "current_level": "yellow",
            "new": "Growing",
            "new_level": "green"
          },
          {
            "dimension": "Competition",
            "current": "Low",
            "current_level": "green",
            "new": "Moderate",
            "new_level": "yellow"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "Ketamine Eases Neuropathic Pain in Clinical Study",
          "source": "Science News",
          "date": "2026-05-22",
          "summary": "Clinical trial reports significant pain reduction in patients treated with low-dose ketamine."
        }
      ],
      "publications": [
        {
          "title": "Ketamine’s role in chronic pain management",
          "journal": "Pain Research & Management",
          "year": 2025,
          "summary": "Clinical review on the efficacy of ketamine infusions for refractory pain conditions."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Ketamine.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/ketamine_chronic_pain_repurposing_report.pdf"
    }
  },
  "pioglitazone_alzheimer": {
    "query": "Evaluate repurposing opportunities for Pioglitazone (small molecule) in Alzheimer's Disease (neurology)",
    "tasks": [
      "Analyze unmet medical needs in Alzheimer's Disease therapy",
      "Assess competitive products and market dynamics for neurology conditions",
      "Search clinical trial registries for studies of Pioglitazone in Alzheimer's Disease",
      "Review patent landscape focusing on Pioglitazone Alzheimer's Disease",
      "Evaluate global market size and growth projections for neurology conditions",
      "Identify key companies and therapies in diabetes to neurodegeneration area",
      "Examine manufacturing and API sourcing considerations for Pioglitazone",
      "Monitor recent scientific publications on Pioglitazone and cognitive decline",
      "Check regulatory status and approvals of Pioglitazone in new indication",
      "Draft strategic recommendations for repurposing Pioglitazone into Alzheimer's Disease"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global Alzheimer's Disease Treatment Market Forecast (USD Billions)",
        "data": [
          {
            "year": "2022",
            "value": 3.2
          },
          {
            "year": "2023",
            "value": 3.4
          },
          {
            "year": "2024",
            "value": 3.7
          },
          {
            "year": "2025",
            "value": 4.0
          },
          {
            "year": "2026",
            "value": 4.4
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2024)",
        "data": [
          {
            "company": "Biogen",
            "share": "40%"
          },
          {
            "company": "Eli Lilly",
            "share": "20%"
          },
          {
            "company": "Roche",
            "share": "15%"
          },
          {
            "company": "Others",
            "share": "~25%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "China",
            "q2_2024": 30,
            "q3_2024": 35,
            "qoq_growth": "+17%"
          },
          {
            "country": "India",
            "q2_2024": 20,
            "q3_2024": 25,
            "qoq_growth": "+25%"
          },
          {
            "country": "UK",
            "q2_2024": 5,
            "q3_2024": 6,
            "qoq_growth": "+20%"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 80
          },
          {
            "year": 2023,
            "price": 82
          },
          {
            "year": 2024,
            "price": 80
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "Generic manufacture; low entry barriers"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Pioglitazone Clinical Trial Landscape",
        "description": "Pioglitazone has been studied in Alzheimer's and neurodegeneration, with some Phase III evidence."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 0,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 3,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 2,
            "color": "amber"
          }
        ],
        "description": "Notable number of trials including completed Phase III studies."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "Takeda",
            "trial_count": 2,
            "focus": "AD Prevention Study"
          },
          {
            "sponsor": "NINDS",
            "trial_count": 1,
            "focus": "Mixed Dementia"
          },
          {
            "sponsor": "Independent Group",
            "trial_count": 2,
            "focus": "Mild Cognitive Impairment"
          }
        ],
        "description": "Industry-led large trials alongside NIH-supported studies."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "Thiazolidinedione patents expired (2018); no CNS-specific claims filed"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "All core patents expired ~2018"
          },
          {
            "label": "FTO Status",
            "value": "Open FTO; new disease claims possible"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "Early Alzheimer's (PPAR-gamma neuroprotection)",
        "medium_risk_areas": "Diabetes-related cognitive decline",
        "low_priority": "Late-stage Alzheimer's"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 1
          },
          {
            "year": 2021,
            "count": 0
          },
          {
            "year": 2022,
            "count": 1
          },
          {
            "year": 2023,
            "count": 1
          },
          {
            "year": 2024,
            "count": 0
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "WO2020123456A1",
          "owner": "Takeda",
          "key_claim": "PPAR agonists for neuroprotection"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "New method-of-use filings for dementia",
          "Develop patentable analogs targeting brain"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "Insulin sensitization may benefit AD pathology"
          },
          {
            "label": "Clinical Signal",
            "value": "Mixed results in trials; benefit likely in mild cases"
          },
          {
            "label": "Patent & Exclusivity",
            "value": "Low, generics available globally"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "Low (Type 2 Diabetes)",
            "current_level": "yellow",
            "new": "Medium",
            "new_level": "yellow"
          },
          {
            "dimension": "Evidence Strength",
            "current": "Moderate",
            "current_level": "green",
            "new": "Limited",
            "new_level": "yellow"
          },
          {
            "dimension": "Cost/Access",
            "current": "High Generic",
            "current_level": "green",
            "new": "High Generic",
            "new_level": "green"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "Clinical Data on Pioglitazone in Mild AD Shows Mixed Results",
          "source": "Alzheimer's Research & Therapy",
          "date": "2026-04-10",
          "summary": "Recent trial reports showed minor cognitive benefits in early-stage patients using Pioglitazone."
        }
      ],
      "publications": [
        {
          "title": "PPAR-gamma agonists in Alzheimer's disease",
          "journal": "Journal of Neuroimmune Pharmacology",
          "year": 2025,
          "summary": "Study exploring how insulin-sensitizing drugs may affect neuroinflammation in AD."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Pioglitazone.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/pioglitazone_alzheimer_repurposing_report.pdf"
    }
  },
  "ivermectin_oncology": {
    "query": "Evaluate repurposing opportunities for Ivermectin (small molecule) in Triple Negative Breast Cancer (oncology)",
    "tasks": [
      "Analyze unmet medical needs in Triple Negative Breast Cancer therapy",
      "Assess competitive products and market dynamics for oncology conditions",
      "Search clinical trial registries for studies of Ivermectin in Triple Negative Breast Cancer",
      "Review patent landscape focusing on Ivermectin Triple Negative Breast Cancer",
      "Evaluate global market size and growth projections for oncology conditions",
      "Identify key companies and therapies in oncology area",
      "Examine manufacturing and API sourcing considerations for Ivermectin",
      "Monitor recent scientific publications on Ivermectin and cancer",
      "Check regulatory status and approvals of Ivermectin in new indication",
      "Draft strategic recommendations for repurposing Ivermectin into Oncology"
    ],
    "IQVIA Insights Agent": {
      "market_forecast": {
        "title": "Global Oncology Drug Market Forecast (USD Billions)",
        "data": [
          {
            "year": "2022",
            "value": 160
          },
          {
            "year": "2023",
            "value": 165
          },
          {
            "year": "2024",
            "value": 173
          },
          {
            "year": "2025",
            "value": 182
          },
          {
            "year": "2026",
            "value": 190
          }
        ]
      },
      "competitive_share": {
        "title": "Competitive Market Share (2024)",
        "data": [
          {
            "company": "Roche",
            "share": "25%"
          },
          {
            "company": "Novartis",
            "share": "20%"
          },
          {
            "company": "Merck",
            "share": "15%"
          },
          {
            "company": "Others",
            "share": "~40%"
          }
        ]
      }
    },
    "EXIM Trade Agent": {
      "trade_volume": {
        "title": "API Trade Volume Analysis",
        "data": [
          {
            "country": "India",
            "q2_2024": 50,
            "q3_2024": 60,
            "qoq_growth": "+20%"
          },
          {
            "country": "China",
            "q2_2024": 40,
            "q3_2024": 45,
            "qoq_growth": "+13%"
          },
          {
            "country": "Thailand",
            "q2_2024": 10,
            "q3_2024": 12,
            "qoq_growth": "+20%"
          }
        ]
      },
      "price_trends": {
        "title": "API Price Trends (USD per kg or per unit)",
        "data": [
          {
            "year": 2022,
            "price": 400
          },
          {
            "year": 2023,
            "price": 390
          },
          {
            "year": 2024,
            "price": 395
          }
        ]
      },
      "import_risks": {
        "title": "Import Risk Assessment",
        "details": "Public controversy; limited branded supply"
      }
    },
    "Clinical Trials Agent": {
      "landscape_overview": {
        "title": "Global Ivermectin Clinical Trial Landscape",
        "description": "Ivermectin's anti-cancer potential is under early investigation, mostly in vitro and small human trials."
      },
      "phase_distribution": {
        "title": "Trial Phase Distribution",
        "data": [
          {
            "phase": "Phase I",
            "count": 1,
            "color": "blue"
          },
          {
            "phase": "Phase II",
            "count": 2,
            "color": "green"
          },
          {
            "phase": "Phase III",
            "count": 0,
            "color": "amber"
          }
        ],
        "description": "Primarily early-phase, mechanism-finding trials in oncology."
      },
      "sponsor_profile": {
        "title": "Sponsor & Research Profile",
        "data": [
          {
            "sponsor": "Biotech Startup",
            "trial_count": 1,
            "focus": "Breast Cancer"
          },
          {
            "sponsor": "Academic Consortium",
            "trial_count": 2,
            "focus": "Various Tumors"
          }
        ],
        "description": "Niche research groups testing Ivermectin's anticancer effects."
      }
    },
    "Patent Landscape Agent": {
      "landscape_overview": {
        "title": "Patent Landscape Overview",
        "sections": [
          {
            "label": "Core Patent Coverage",
            "value": "Ivermectin patents long expired (1980s); no oncology-specific IP exists"
          },
          {
            "label": "Patent Expiry Timeline",
            "value": "Expired decades ago"
          },
          {
            "label": "FTO Status",
            "value": "Open FTO; only new formulations or combos patentable"
          }
        ]
      },
      "repurposing_strategy": {
        "title": "Strategic Repurposing Patent Strategy",
        "high_confidence_targets": "Breast and prostate cancer (in vitro evidence)",
        "medium_risk_areas": "Other solid tumors",
        "low_priority": "Liquid tumors"
      },
      "filing_heatmap": {
        "title": "Patent Filings Over Time",
        "data": [
          {
            "year": 2020,
            "count": 0
          },
          {
            "year": 2021,
            "count": 1
          },
          {
            "year": 2022,
            "count": 0
          },
          {
            "year": 2023,
            "count": 0
          },
          {
            "year": 2024,
            "count": 0
          }
        ],
        "description": "Filing trends indicate attention to related research areas."
      },
      "key_patent_extract": [
        {
          "patent": "US33445566B2",
          "owner": "Academic",
          "key_claim": "Ivermectin derivatives for cancer"
        }
      ],
      "ip_opportunities": {
        "title": "Key IP Opportunities",
        "list": [
          "Develop novel analogs with patent protection",
          "File method-of-use for specific cancers"
        ]
      }
    },
    "Internal Knowledge Agent": {
      "strategic_synthesis": {
        "title": "Internal Knowledge Base – Strategic Synthesis",
        "insights": [
          {
            "label": "Mechanism Fit",
            "value": "Hyperforin channel modulation in cancer cells (still theoretical)"
          },
          {
            "label": "Clinical Evidence",
            "value": "Very preliminary; mainly cell/animal data"
          },
          {
            "label": "Regulatory Challenges",
            "value": "Controversial safety profile; high skepticism"
          }
        ]
      },
      "cross_indication_comparison": {
        "title": "Cross-Indication Strategic Comparison",
        "dimensions": [
          {
            "dimension": "Commercial Readiness",
            "current": "High (Parasitic use)",
            "current_level": "green",
            "new": "Very Low",
            "new_level": "red"
          },
          {
            "dimension": "Clinical Credibility",
            "current": "High",
            "current_level": "green",
            "new": "Very Low",
            "new_level": "red"
          },
          {
            "dimension": "Risk Profile",
            "current": "Low",
            "current_level": "green",
            "new": "Moderate",
            "new_level": "yellow"
          }
        ]
      }
    },
    "Web Intelligence Agent": {
      "news": [
        {
          "headline": "Study Finds Ivermectin Inhibits Breast Cancer Cell Growth",
          "source": "Cancer Research UK",
          "date": "2025-07-18",
          "summary": "Laboratory study reports Ivermectin's effect on breast cancer cell apoptosis."
        }
      ],
      "publications": [
        {
          "title": "Ivermectin as an anticancer agent: mechanisms and perspectives",
          "journal": "Oncotarget",
          "year": 2025,
          "summary": "Review of Ivermectin's potential mechanisms in cancer therapy."
        }
      ]
    },
    "Report Generator Agent": {
      "title": "Report Compilation Progress",
      "description": "Synthesizing insights from all analyses to produce a comprehensive repurposing report for Ivermectin.",
      "sections": [
        {
          "title": "Executive Summary",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Market & Competitive Analysis",
          "status": "Complete",
          "color": "blue"
        },
        {
          "title": "Clinical & Mechanistic Rationale",
          "status": "Complete",
          "color": "green"
        },
        {
          "title": "Intellectual Property & FTO",
          "status": "In Progress",
          "color": "amber"
        },
        {
          "title": "Final Report Status",
          "status": "Finalizing",
          "color": "amber"
        }
      ],
      "report_file": "/reports/ivermectin_oncology_repurposing_report.pdf"
    }
  },
  "free_data_sources": {
    "IQVIA Insights Agent": [
      {
        "name": "World Bank Open Data",
        "url": "https://data.worldbank.org",
        "description": "Global economic and health statistics from the World Bank."
      },
      {
        "name": "OECD Data API",
        "url": "https://data.oecd.org/api/sdmx-json-documentation",
        "description": "Free API access to OECD health and economic indicators."
      },
      {
        "name": "WHO Global Health Observatory",
        "url": "https://www.who.int/data/gho/info/gho-odata-api",
        "description": "WHO's open data for health statistics and disease burden."
      }
    ],
    "EXIM Trade Agent": [
      {
        "name": "UN Comtrade API",
        "url": "https://comtrade.un.org",
        "description": "International trade data (free up to 100K records per call)."
      },
      {
        "name": "World Bank WITS API",
        "url": "https://wits.worldbank.org",
        "description": "World Bank WITS API for trade and tariff data."
      },
      {
        "name": "U.S. Census International Trade API",
        "url": "https://api.census.gov/data.html",
        "description": "Free U.S. international trade data API."
      }
    ],
    "Clinical Trials Agent": [
      {
        "name": "ClinicalTrials.gov API",
        "url": "https://clinicaltrials.gov/api/",
        "description": "Registry of clinical trials; public REST API available."
      },
      {
        "name": "WHO ICTRP",
        "url": "https://trialsearch.who.int",
        "description": "WHO clinical trials registry portal covering global trial registries."
      },
      {
        "name": "EU Clinical Trials Register (EudraCT)",
        "url": "https://www.clinicaltrialsregister.eu/",
        "description": "EU database of clinical trials for medicinal products."
      }
    ],
    "Patent Landscape Agent": [
      {
        "name": "EPO Open Patent Services (OPS)",
        "url": "https://www.epo.org/en/searching-for-patents/data/web-services/ops",
        "description": "Free API for EPO patent data (up to 4GB/week free)."
      },
      {
        "name": "USPTO Patent Public Data",
        "url": "https://developer.uspto.gov/",
        "description": "USPTO Open Data Portal for patents (free access to USPTO patents)."
      },
      {
        "name": "The Lens Patent API",
        "url": "https://www.lens.org",
        "description": "Lens.org provides patent and scholarly data APIs (free with registration)."
      }
    ],
    "Internal Knowledge Agent": [
      {
        "name": "PubChem",
        "url": "https://pubchem.ncbi.nlm.nih.gov",
        "description": "NIH database of chemical molecules (drug structures, targets, bioactivity)."
      },
      {
        "name": "OpenFDA",
        "url": "https://open.fda.gov/",
        "description": "FDA open APIs including drug labels, adverse events, manufacturer info."
      },
      {
        "name": "NIH RePORTER",
        "url": "https://reporter.nih.gov/",
        "description": "Database of NIH-funded research projects; public API for research grant data."
      }
    ],
    "Web Intelligence Agent": [
      {
        "name": "PubMed (NCBI E-utilities)",
        "url": "https://pubmed.ncbi.nlm.nih.gov",
        "description": "Entrez Programming Utilities for PubMed and other NCBI databases."
      },
      {
        "name": "Europe PMC",
        "url": "https://europepmc.org",
        "description": "Europe PubMed Central API for biomedical and life sciences literature."
      },
      {
        "name": "NewsAPI.org",
        "url": "https://newsapi.org",
        "description": "News aggregator API (free tier with key for retrieving news articles)."
      }
    ]
  }
}
